Ethyl Icosapentate
Phase 3Small molecule
Ethyl Icosapentate is one of 73 small molecule programs targeting Physical Activity. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Lopid
PfizerApproved
Cipro
BayerApproved
Selzentry
GSKApproved
Crestor
AstraZenecaApproved
Topamax
WWim Janssens
Approved
Zocor
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zetia
OOrganon and Co
Phase 3
Statin
Bristol-Myers SquibbPhase 3
EVKEEZA
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ethyl Icosapentate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details